ABSTRACT
Objectives Sj□gren’s disease (SjD) diagnosis requires either positive anti-SSA antibodies or a labial salivary gland biopsy with a positive focus score (FS). One-third of SjD patients lack anti-SSA antibodies (SSA-), requiring a positive FS for diagnosis. Our objective was to identify novel autoantibodies to diagnose ‘seronegative’ SjD.
Methods IgG binding to a high density whole human peptidome array was quantified using sera from SSA- SjD cases and matched non-autoimmune controls. We identified the highest bound peptides using empirical Bayesian statistical filters, which we confirmed in an independent cohort comprising SSA- SjD (n=76), sicca controls without autoimmunity (n=75), and autoimmune controls (SjD features but not meeting SjD criteria; n=41). In this external validation, we used non-parametric methods for peptide abundance and controlled false discovery rate in group comparisons. For predictive modeling, we used logistic regression, model selection methods, and cross-validation to identify clinical and peptide variables that predict SSA- SjD and FS positivity.
Results IgG against a peptide from D-aminoacyl-tRNA deacylase (DTD2) was bound more in SSA- SjD than sicca controls (p=.004) and more than combined controls (sicca and autoimmune controls combined; p=0.003). IgG against peptides from retroelement silencing factor-1 (RESF1) and DTD2, were bound more in FS-positive than FS-negative participants (p=.010; p=0.012). A predictive model incorporating clinical variables showed good discrimination between SjD versus control (AUC 74%) and between FS-positive versus FS-negative (AUC 72%).
Conclusion We present novel autoantibodies in SSA- SjD that have good predictive value for SSA- SjD and FS-positivity.
KEY MESSAGES
What is already known on this topic - Seronegative (anti-SSA antibody negative [SSA-]) Sjögren’s disease (SjD) requires a labial salivary gland biopsy for diagnosis, which is challenging to obtain and interpret.
What this study adds - We identified novel autoantibodies in SSA- SjD that, when combined with readily available clinical variables, provide good predictive ability to discriminate 1) SSA- SjD from control participants and 2) abnormal salivary gland biopsies from normal salivary gland biopsies.
How this study might affect research, practice or policy - This study provides novel diagnostic antibodies addressing the critical need for improvement of SSA- SjD diagnostic tools.
Competing Interest Statement
Dr. McCoy declares consulting for Novartis, Horizon, Target RWE, Otsuka/Visterra, Kiniksa, BMS, and iCELL
Funding Statement
Funding: Support for this research was provided by the Sjogrens Foundation and University of Wisconsin-Madison, Discovery to Product (D2P) with funding from the Wisconsin Alumni Research Foundation (SSM) and the University of Wisconsin-Madison, Office of the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation (MAS). Additional support was provided by the Clinical and Translational Science Award program through the NIH NCATS (1KL2TR002374) (SSM), U.S. Army Medical Research Acquisition Activity through the Peer Reviewed Medical Research Program [W81XWH-18-1-0717] (MAS), The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The data reported herein have been supplied by the Sjogrens International Collaborative Clinical Alliance (SICCA) Biorepository by the National Institute of Dental and Craniofacial Research (contract HHSN26S201300057C). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the SICCA investigators or the National Institute of Dental and Craniofacial Research. Conflicts of Interest: the authors do not have any conflicts of interest to declare relating to this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In addition to IRB approval obtained for each SICCA clinical research site, and all foreign institutions housing these sites having Federal wide Assurance, we obtained IRB approval from the UW health sciences IRB (IRB # 2021-0945) to perform the analyses presented in this paper.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: Support for this research was provided by the Sjögren’s Foundation and University of Wisconsin-Madison, Discovery to Product (D2P) with funding from the Wisconsin Alumni Research Foundation (SSM) and the University of Wisconsin-Madison, Office of the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation (MAS). Additional support was provided by the Clinical and Translational Science Award program through the NIH NCATS (1KL2TR002374) (SSM), U.S. Army Medical Research Acquisition Activity through the Peer Reviewed Medical Research Program [W81XWH-18-1-0717] (MAS), The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The data reported herein have been supplied by the Sjögren’s International Collaborative Clinical Alliance (SICCA) Biorepository by the National Institute of Dental and Craniofacial Research (contract HHSN26S201300057C). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the SICCA investigators or the National Institute of Dental and Craniofacial Research.
Conflicts of Interest: the authors do not have any conflicts of interest to declare relating to this work
Ethics approval: This study was approved by the University of Wisconsin Health Sciences IRB (IRB# 2021-0821 and IRB# 2015-0156)
Presented at: Preliminary results from this study have been presented by McCoy S, et al. Novel autoantibodies identified in seronegative Sjögren’s using innovative whole peptidome array technology. At the International Symposium on Sjögren’s Syndrome, Rome, Italy, 7-10 September 2022.
Data Availability
all data produced in the present study are availbe upon reasonable request to the authors
